Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

Haematologica. 2013 Jul;98(7):1098-106. doi: 10.3324/haematol.2012.074781. Epub 2013 Feb 12.

Abstract

The nuclear export protein chromosome maintenance region 1, found to be elevated in non-Hodgkin's lymphomas, controls localization of critical tumor suppressor proteins. Nuclear localization of tumor suppressor proteins is necessary for their cell surveillance function. However, their nuclear exclusion by chromosome maintenance region 1 renders them ineffective making this nuclear transporter an attractive therapeutic target. We have identified selective inhibitors of nuclear export that lock tumor suppressor proteins in the cell nucleus leading to apoptosis of lymphoid but not normal cells. Our inhibitors induce tumor suppressor protein nuclear retention-dependent growth inhibition and apoptosis in a panel of non-Hodgkin's lymphoma cell lines. Western blot of nuclear protein fraction and confocal microscopy analysis demonstrated retention of major tumor suppressor proteins in the cell nucleus. Co-immunoprecipitation studies showed disruption of the tumor suppressor protein-chromosome maintenance region 1 interaction. Small inhibitor RNA knockdown of two major tumor suppressor proteins, p53 in wild-type protein-53 and protein 73 in mutant-protein-53, abrogated inhibitor activity. Oral administration of related inhibitor at 75 and 150 mg/kg resulted in 65 and 70% tumor reduction, respectively and subcutaneous injections of inhibitor (25 and 75 mg/kg) resulted in 70 and 74% suppression of non-Hodgkin's lymphoma tumor growth with no toxicity; residual tumors showed activation of the protein 73 pathway. Our study verifies chromosome maintenance region 1 as a therapeutic target in non-Hodgkin's lymphoma, indicating that this nuclear export protein warrants further clinical investigations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylates / chemistry
  • Acrylates / pharmacology
  • Acrylates / therapeutic use
  • Active Transport, Cell Nucleus / drug effects*
  • Active Transport, Cell Nucleus / physiology
  • Animals
  • Exportin 1 Protein
  • Humans
  • Karyopherins / antagonists & inhibitors*
  • Karyopherins / metabolism*
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / metabolism
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / metabolism*
  • Mice
  • Mice, SCID
  • Receptors, Cytoplasmic and Nuclear / antagonists & inhibitors*
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Treatment Outcome
  • Triazoles / chemistry
  • Triazoles / pharmacology
  • Triazoles / therapeutic use
  • Tumor Cells, Cultured
  • Waldenstrom Macroglobulinemia / drug therapy
  • Waldenstrom Macroglobulinemia / metabolism
  • Xenograft Model Antitumor Assays / methods

Substances

  • Acrylates
  • KPT-185
  • Karyopherins
  • Receptors, Cytoplasmic and Nuclear
  • Triazoles